Holen Sie sich die Stockscreener-App
3.76
0.27%
0.010
Schlusskurs vom Vortag:
$3.75
Offen:
$3.91
24-Stunden-Volumen:
158.90K
Relative Volume:
0.34
Marktkapitalisierung:
$38.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1912
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
+7.43%
1M Leistung:
+14.63%
6M Leistung:
+16.05%
1J Leistung:
+8.99%
1-Tages-Spanne:
$3.70
$3.91
1-Wochen-Bereich:
$3.485
$3.91
52-Wochen-Spanne:
$2.30
$4.42
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.76 | 35.67M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
What drives PolyPid Ltd. stock priceDouble or triple returns - Autocar Professional
What analysts say about PolyPid Ltd. stockUnmatched profit growth - jammulinksnews.com
PolyPid Ltd. Stock Analysis and ForecastSuperior stock growth - jammulinksnews.com
Is PolyPid Ltd. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes Market - The Globe and Mail
PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits - Yahoo Finance
PolyPid's Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market - openPR.com
How PolyPid Ltd. stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
What makes PolyPid Ltd. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Analysts Set PolyPid Ltd. (NASDAQ:PYPD) Price Target at $11.80 - Defense World
Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech - The Manila Times
PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment - Investing.com Australia
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists - GlobeNewswire
Revolutionary 60-Day GLP-1 Injection Could Replace Weekly Diabetes Treatments, PolyPid Announces - Stock Titan
Why PolyPid Ltd. stock attracts strong analyst attentionReliable Low Risk Signals - Newser
PolyPid (NASDAQ:PYPD) Raised to “Hold” at Wall Street Zen - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Down 0.6% – Here’s What Happened - Defense World
Is PolyPid Stock Undervalued? (NASDAQ: PYPD) - newsblaze.com
PolyPid Announces $26.7 Million Warrant Inducement Transaction - Global Legal Chronicle
PolyPid Approves Key Resolutions at Annual Shareholder Meeting - TipRanks
Brokerages Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.25 - Defense World
PolyPid (NASDAQ:PYPD) Given a $9.00 Price Target by Roth Capital Analysts - Defense World
Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener
Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus
PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World
PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus
PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus
PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa
PolyPid stock price target lowered to $14 at JMP on warrant dilution - Investing.com Australia
PolyPid Secures $26.7 Million Post-Successful Phase 3 Trial - TipRanks
Citizens JMP Adjusts Price Target for PolyPid (PYPD) Amid Warrant Developments | PYPD Stock News - GuruFocus
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results - GlobeNewswire
PolyPid Secures $26.7M Funding Following Breakthrough Phase 3 Results in Surgical Infection Prevention - Stock Titan
FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PESG Research Update: PolyPid SHIELD’s II Delivers - GlobeNewswire
PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline ResultsParadigm Shift in Surgical Infection Prevention - Yahoo
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):